1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one

Request For Quotation
1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one manufacturers

  • NR2F1 agonist 1
  • NR2F1 agonist 1 pictures
  • $2180.00
  • 2026-07-15
  • CAS:374101-64-1
  • Purity:
  • Supply Ability: 10g
1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Basic information
Product Name:1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one
Synonyms:1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one;Spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6(4H),1'-cyclohexan]-5(7H)-one, 1-(ethylthio)-4-(2-phenylethyl)-;NR2F1 agonist 1
CAS:374101-64-1
MF:C28H30N4OS
MW:470.63
EINECS:
Product Categories:
Mol File:374101-64-1.mol
1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Structure
1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Chemical Properties
Boiling point 719.9±70.0 °C(Predicted)
density 1.31±0.1 g/cm3(Predicted)
pka1.47±0.20(Predicted)
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Usage And Synthesis
UsesNR2F1 agonist 1, a nuclear receptor NR2F1 agonist, specifically activates dormancy programs in malignant cells. NR2F1 agonist 1 up-regulates NR2F1 and downstream target genes that regulate dormancy. NR2F1 agonist 1 induces neural crest-like and growth suppression in head and neck squamous cell carcinoma (HNSCC) via NR2F1 activation. NR2F1 agonist 1 inhibits tumor growth in a mouse primary tumor model[1].
in vivo

NR2F1 agonist 1 (0.5 mg/kg/day; i.p.; 3 weeks) inhibits inhibits primary tumor growth and metastatic growth in lungs in mouse models[1].

Animal Model:BALB/c nu/nu mice bearing GFP-tagged T-HEp3 PDX cells[1]
Dosage:0.5 mg/kg/day
Administration:Intraperitoneal injection; injected for 3 weeks or for 1 week followed by DMSO for 2 weeks
Result:Did not induce apoptosis of proliferating primary tumor cells, but exhibited metastasis inhibitory effect against T-HEp3 cells.
References[1] Khalil BD, et al. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022 Jan 3;219(1):e20210836. DOI:10.1084/jem.20210836
1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one Preparation Products And Raw materials
Tag:1-(ethylthio)-4-phenethyl-4H-spiro[benzo[h][1,2,4]triazolo[4,3-a]quinazoline-6,1'-cyclohexan]-5(7H)-one(374101-64-1) Related Product Information
SS-RJW100 Ethyl2-[[2-[2-[(2,3-Dihydro-1,4-benzodioxin-6-yl)amino]-2-oxoethyl]-1,2-dihydro-1-oxo-5-isoquinolinyl]oxy]propanoate Anti-cancer compound library 4(1H)-Quinazolinone, 2,3-dihydro-2-(2-naphthalenyl)-6-(trifluoromethoxy)-, (2S)- Ethanone, 1-[3'-[1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl][1,1'-biphenyl]-3-yl]- 4,6-Dioxa-10-aza-5-phosphatridecanoic acid, 2-amino-5,8-dihydroxy-3-methyl-11-oxo-13-[3-(undecyloxy)phenyl]-, 5-oxide, (2S,3S,8R)-